192 related articles for article (PubMed ID: 16714300)
1. Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity.
Hampe C; Ardila-Osorio H; Fournier M; Brice A; Corti O
Hum Mol Genet; 2006 Jul; 15(13):2059-75. PubMed ID: 16714300
[TBL] [Abstract][Full Text] [Related]
2. Differential interaction of the E3 ligase parkin with the proteasomal subunit S5a and the endocytic protein Eps15.
Safadi SS; Shaw GS
J Biol Chem; 2010 Jan; 285(2):1424-34. PubMed ID: 19875440
[TBL] [Abstract][Full Text] [Related]
3. Regulation of Parkin E3 ubiquitin ligase activity.
Walden H; Martinez-Torres RJ
Cell Mol Life Sci; 2012 Sep; 69(18):3053-67. PubMed ID: 22527713
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease.
da Costa CA; Sunyach C; Giaime E; West A; Corti O; Brice A; Safe S; Abou-Sleiman PM; Wood NW; Takahashi H; Goldberg MS; Shen J; Checler F
Nat Cell Biol; 2009 Nov; 11(11):1370-5. PubMed ID: 19801972
[TBL] [Abstract][Full Text] [Related]
5. Design and high-throughput implementation of MALDI-TOF/MS-based assays for Parkin E3 ligase activity.
Traynor R; Moran J; Stevens M; Antico O; Knebel A; Behrouz B; Merchant K; Hastie CJ; Davies P; Muqit MMK; De Cesare V
Cell Rep Methods; 2024 Feb; 4(2):100712. PubMed ID: 38382522
[TBL] [Abstract][Full Text] [Related]
6. Probes of ubiquitin E3 ligases enable systematic dissection of parkin activation.
Pao KC; Stanley M; Han C; Lai YC; Murphy P; Balk K; Wood NT; Corti O; Corvol JC; Muqit MM; Virdee S
Nat Chem Biol; 2016 May; 12(5):324-31. PubMed ID: 26928937
[TBL] [Abstract][Full Text] [Related]
7. Disruption of the autoinhibited state primes the E3 ligase parkin for activation and catalysis.
Kumar A; Aguirre JD; Condos TE; Martinez-Torres RJ; Chaugule VK; Toth R; Sundaramoorthy R; Mercier P; Knebel A; Spratt DE; Barber KR; Shaw GS; Walden H
EMBO J; 2015 Oct; 34(20):2506-21. PubMed ID: 26254304
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin Carboxyl-Terminal Hydrolase L1 and Its Role in Parkinson's Disease.
Buneeva O; Medvedev A
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279302
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Iron Homeostasis through Parkin-Mediated Lactoferrin Ubiquitylation.
Gholkar AA; Schmollinger S; Velasquez EF; Lo YC; Cohn W; Capri J; Dharmarajan H; Deardorff WJ; Gao LW; Abdusamad M; Whitelegge JP; Torres JZ
Biochemistry; 2020 Aug; 59(32):2916-2921. PubMed ID: 32786404
[TBL] [Abstract][Full Text] [Related]
10. PARKIN is not required to sustain OXPHOS function in adult mammalian tissues.
Filograna R; Gerlach J; Choi HN; Rigoni G; Barbaro M; Oscarson M; Lee S; Tiklova K; Ringnér M; Koolmeister C; Wibom R; Riggare S; Nennesmo I; Perlmann T; Wredenberg A; Wedell A; Motori E; Svenningsson P; Larsson NG
NPJ Parkinsons Dis; 2024 Apr; 10(1):93. PubMed ID: 38684669
[TBL] [Abstract][Full Text] [Related]
11. Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65.
Kazlauskaite A; Kondapalli C; Gourlay R; Campbell DG; Ritorto MS; Hofmann K; Alessi DR; Knebel A; Trost M; Muqit MM
Biochem J; 2014 May; 460(1):127-39. PubMed ID: 24660806
[TBL] [Abstract][Full Text] [Related]
12. RBR E3 ubiquitin ligases: new structures, new insights, new questions.
Spratt DE; Walden H; Shaw GS
Biochem J; 2014 Mar; 458(3):421-37. PubMed ID: 24576094
[TBL] [Abstract][Full Text] [Related]
13. Structure of parkin reveals mechanisms for ubiquitin ligase activation.
Trempe JF; Sauvé V; Grenier K; Seirafi M; Tang MY; Ménade M; Al-Abdul-Wahid S; Krett J; Wong K; Kozlov G; Nagar B; Fon EA; Gehring K
Science; 2013 Jun; 340(6139):1451-5. PubMed ID: 23661642
[TBL] [Abstract][Full Text] [Related]
14. PRKN-linked familial Parkinson's disease: cellular and molecular mechanisms of disease-linked variants.
Clausen L; Okarmus J; Voutsinos V; Meyer M; Lindorff-Larsen K; Hartmann-Petersen R
Cell Mol Life Sci; 2024 May; 81(1):223. PubMed ID: 38767677
[TBL] [Abstract][Full Text] [Related]
15. A mutational atlas for Parkin proteostasis.
Clausen L; Voutsinos V; Cagiada M; Johansson KE; Grønbæk-Thygesen M; Nariya S; Powell RL; Have MKN; Oestergaard VH; Stein A; Fowler DM; Lindorff-Larsen K; Hartmann-Petersen R
Nat Commun; 2024 Feb; 15(1):1541. PubMed ID: 38378758
[TBL] [Abstract][Full Text] [Related]
16. Activation of Ca
Marchesan E; Nardin A; Mauri S; Bernardo G; Chander V; Di Paola S; Chinellato M; von Stockum S; Chakraborty J; Herkenne S; Basso V; Schrepfer E; Marin O; Cendron L; Medina DL; Scorrano L; Ziviani E
Cell Death Differ; 2024 Feb; 31(2):217-238. PubMed ID: 38238520
[TBL] [Abstract][Full Text] [Related]
17. Role of Deubiquitinases in Parkinson's Disease-Therapeutic Perspectives.
Nielsen PYØ; Okarmus J; Meyer M
Cells; 2023 Feb; 12(4):. PubMed ID: 36831318
[TBL] [Abstract][Full Text] [Related]
18. CK2 and protein kinases of the CK1 superfamily as targets for neurodegenerative disorders.
Baier A; Szyszka R
Front Mol Biosci; 2022; 9():916063. PubMed ID: 36275622
[TBL] [Abstract][Full Text] [Related]
19. Selective localization of Mfn2 near PINK1 enables its preferential ubiquitination by Parkin on mitochondria.
Vranas M; Lu Y; Rasool S; Croteau N; Krett JD; Sauvé V; Gehring K; Fon EA; Durcan TM; Trempe JF
Open Biol; 2022 Jan; 12(1):210255. PubMed ID: 35042405
[TBL] [Abstract][Full Text] [Related]
20. Investigation of USP30 inhibition to enhance Parkin-mediated mitophagy: tools and approaches.
Tsefou E; Walker AS; Clark EH; Hicks AR; Luft C; Takeda K; Watanabe T; Ramazio B; Staddon JM; Briston T; Ketteler R
Biochem J; 2021 Dec; 478(23):4099-4118. PubMed ID: 34704599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
